Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 2/20 | 0.49 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.42 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.41 |
| ▸ | CDC7 | O00311 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | CHUK | O15111 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.38 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.38 |
| ▸ | CLK1 | P49759 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.37 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.37 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.36 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.36 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.36 |
| ▸ | CDK9 | P50750 | 1/20 | 0.36 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27893482 | 0.98 | HPGDS (0.47) | HPGDSCYP11B2CYP11B1CYP17A1CDC7 | |
| Trifluoroacetic Acid SCHEMBL30365424 | 0.85 | GPR6 (0.40) | HPGDSCYP11B2CYP11B1DYRK1A | |
| SCHEMBL5118002 | 0.85 | HPGDS (0.53) | HPGDSCYP11B2CYP11B1CYP17A1CDC7 | |
| Isoquinoline SCHEMBL27659278 | 0.84 | PDGFRB (0.47) | HPGDSCYP11B2CYP11B1CYP17A1HTT | |
| SCHEMBL28292066 | 0.84 | HPGDS (0.51) | HPGDSCYP11B2CYP11B1CYP17A1CDC7 | |
| SCHEMBL2012640 | 0.81 | EGFR (0.38) | HPGDSHTTEGFRCSNK1DCSNK1E | |
| SCHEMBL27856310 | 0.81 | HDAC8 (0.43) | HTTEGFRCSNK1DCSNK1ECLK1 | |
| SCHEMBL30853054 | 0.78 | EGFR (0.55) | HPGDSCYP11B2CYP11B1CYP17A1CDC7 | |
| SCHEMBL30618089 | 0.78 | EGFR (0.55) | HPGDSCYP11B2CYP11B1CYP17A1CDC7 | |
| SCHEMBL3393275 | 0.78 | EGFR (0.55) | HPGDSCYP11B2CYP11B1CYP17A1CDC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2696682-A2 | MIF INHIBITORS AND THEIR USES | Innovimmune Biotherapeutics, Inc. (US) | 2014-02-19 | — | — | EP | claimed |
| WO-2012142498-A2 | MIF INHIBITORS AND THEIR USES | INNOVIMMUNE BIOTHERAPEUTICS, INC. (US) | 2012-10-18 | — | — | WO | claimed |
| US-20050107350-A1 | Method for the treatment or prevention of bone disorders with a cyclooxygenase-2 inhibitor alone and in combination with a bone disorder treatment agent and compositions therewith | PHARMACIA CORPORATION (US) | 2005-05-19 | — | — | US | claimed |
| EP-4541794-A1 | PHENYL-SUBSTITUTED DIHYDRONAPHTHYRIDINE COMPOUNDS, AND PREPARATION AND USE THEREOF | Suzhong Pharmaceutical Group Co., Ltd. (CN) | 2025-04-23 | — | — | EP | disclosed |
| WO-2025011008-A1 | PHARMACEUTICAL PREPARATION CONTAINING PHENYL-SUBSTITUTED DIHYDRONAPHTHYRIDINE COMPOUND, AND USE THEREOF | 苏中药业集团股份有限公司 | 2025-01-16 | — | — | WO | disclosed |
| WO-2024061333-A1 | KRAS MUTANT PROTEIN INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | 甘李药业股份有限公司 | 2024-03-28 | — | — | WO | disclosed |
| WO-2024022481-A1 | PHENYL-SUBSTITUTED DIHYDRONAPHTHYRIDINE COMPOUNDS, AND PREPARATION AND USE THEREOF | 苏中药业集团股份有限公司 | 2024-02-01 | — | — | WO | disclosed |
| WO-2023138583-A1 | HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION AND USE THEREOF | 上海湃隆生物科技有限公司 | 2023-07-27 | — | — | WO | disclosed |
| WO-2022116943-A1 | SUBSTITUTED FUSED BICYCLIC COMPOUND AS KINASE INHIBITOR AND USE THEREOF | 上海瑛派药业有限公司 | 2022-06-09 | — | — | WO | disclosed |
| EP-2603218-B1 | QUINOLYL AMINES AS KINASE INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2016-03-02 | — | — | EP | disclosed |
| EP-2696682-A2 | MIF INHIBITORS AND THEIR USES | Innovimmune Biotherapeutics, Inc. (US) | 2014-02-19 | — | — | EP | disclosed |
| US-6689772-B1 | ANTINEOPLASTIC AGENTS; OSTEOPOROSIS; POLYCYSTIC KIDNEY DISEASE; ANTIVIRAL AGENTS | WYETH | 2004-02-10 | — | — | US | disclosed |
| US-6689772-B1 | ANTINEOPLASTIC AGENTS; OSTEOPOROSIS; POLYCYSTIC KIDNEY DISEASE; ANTIVIRAL AGENTS | WYETH | 2004-02-10 | — | — | US | disclosed |
| CN-1419545-A | 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors | WYETH CORP (US) | 2003-05-21 | — | — | CN | disclosed |
| US-6521618-B2 | Antineoplastic agents, agents for treatment of osteoporosis and polycystic kidney disease | WYETH | 2003-02-18 | — | — | US | disclosed |
| US-6521618-B2 | Antineoplastic agents, agents for treatment of osteoporosis and polycystic kidney disease | WYETH | 2003-02-18 | — | — | US | disclosed |
| EP-1268431-A1 | 3-CYANOQUINOLINES,3-CYANO-1,6-NAPHTHYRIDINES, AND 3-CYANO-1,7-NAPHTHYRIDINES AS PROTEIN KINASE INHIBITORS | Wyeth (US) | 2003-01-02 | — | — | EP | disclosed |
| US-20020026052-A1 | 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors | AMERICAN HOME PRODUCTS CORPORATION (US) | 2002-02-28 | — | — | US | disclosed |
| US-20020026052-A1 | 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors | AMERICAN HOME PRODUCTS CORPORATION (US) | 2002-02-28 | — | — | US | disclosed |
| WO-2001072711-A1 | 3-CYANOQUINOLINES,3-CYANO-1,6-NAPHTHYRIDINES, AND 3-CYANO-1,7-NAPHTHYRIDINES AS PROTEIN KINASE INHIBITORS | WYETH (US) | 2001-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107350-A1 | Method for the treatment or prevention of bone disorders with a cyclooxygenase-2 inhibitor alone and in combination with a bone disorder treatment agent and compositions therewith | PTGS2, PTGES2, PTGS1 | HPGDS 10/4885CYP11B2 412/4885CYP11B1 1006/4885 |
| US-20020026052-A1 | 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors | PKD1, PKD2, CSNK1A1 | HPGDS 2403/4885CYP11B2 3302/4885CYP11B1 2866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.